Literature DB >> 23385353

An inactivated vaccine from a field strain of bovine herpesvirus-1 (BoHV-1) has high antigenic mass and induces strong efficacy in a rabbit model.

Julian Ruiz-Sáenz1, Jairo Jaime, Victor Vera.   

Abstract

Bovine Herpesvirus-1 (BoHV-1) is a DNA virus belonging to the family Herpesviridae, subfamily Alfaherpesvirinae; it is a worldwide pathogen, causing serious economic losses in livestock. In Colombia there have been multiple isolates of BoHV-1 that have been subjected to molecular characterization, classifying most of the country isolates as BoHV-1.1. In the present study we developed and evaluated an ethyleneimine binary inactivated isolate from the native BoHV-1 strain (Córdoba-2) in a rabbit model of vaccination and infection. The vaccine was evaluated in two phases, one of immunogenicity with vaccination and a booster after 21 days, and an evaluation phase of protection against challenge with a highly virulent reference strain. The results demonstrate optimum serum-conversion, with protective neutralizing antibody titers 28 days post vaccination and optimal protection against challenge with the reference strain with decreased clinical signs of infection, protection against the onset of fever and decrease of virus excretion post challenge. In conclusion, our results show the enormous potential that an immunogenic inactivated vaccine has produced from the native BoHV-1.1 strain, which produces a high antigen mass to the vaccine to induce optimal immunity and protection, and it is a strong candidate for evaluation and possible future use in different cattle populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23385353      PMCID: PMC8208363          DOI: 10.1007/s12250-013-3283-z

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  23 in total

1.  Molecular and in vitro characterization of field isolates of bovine herpesvirus-1.

Authors:  Julian Ruiz-Saenz; Jairo Jaime; Gloria Ramirez; Victor Vera
Journal:  Virol Sin       Date:  2012-01-22       Impact factor: 4.327

2.  Relative efficacy of inactivated bovine herpesvirus-1 (BHV-1) vaccines.

Authors:  J R Patel
Journal:  Vaccine       Date:  2005-01-09       Impact factor: 3.641

3.  Prime-boost strategies combining DNA and inactivated vaccines confer high immunity and protection in cattle against bovine herpesvirus-1.

Authors:  J F Toussaint; C Letellier; D Paquet; M Dispas; P Kerkhofs
Journal:  Vaccine       Date:  2005-10-17       Impact factor: 3.641

4.  Intraspecific bovine herpesvirus 1 recombinants carrying glycoprotein E deletion as a vaccine marker are virulent in cattle.

Authors:  Benoît Muylkens; François Meurens; Frédéric Schynts; Frédéric Farnir; Aldo Pourchet; Marjorie Bardiau; Sacha Gogev; Julien Thiry; Adeline Cuisenaire; Alain Vanderplasschen; Etienne Thiry
Journal:  J Gen Virol       Date:  2006-08       Impact factor: 3.891

5.  Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV, and BRSV in experimentally infected calves.

Authors:  A R Peters; S J Thevasagayam; A Wiseman; J S Salt
Journal:  Prev Vet Med       Date:  2004-12-15       Impact factor: 2.670

6.  Serological response in cattle immunized with inactivated oil and Algel adjuvant vaccines against infectious bovine rhinotracheitis.

Authors:  G Kamaraj; S K Rana; V A Srinivasan
Journal:  New Microbiol       Date:  2009-04       Impact factor: 2.479

7.  A simple method of infecting rabbits with Bovine herpesvirus 1 and 5.

Authors:  A R Valera; C L Pidone; A R Massone; M A Quiroga; J G Riganti; S G Corva; C M Galosi
Journal:  J Virol Methods       Date:  2008-04-21       Impact factor: 2.014

8.  The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides.

Authors:  X P Ioannou; P Griebel; R Hecker; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  The order Herpesvirales.

Authors:  Andrew J Davison; Richard Eberle; Bernhard Ehlers; Gary S Hayward; Duncan J McGeoch; Anthony C Minson; Philip E Pellett; Bernard Roizman; Michael J Studdert; Etienne Thiry
Journal:  Arch Virol       Date:  2008-12-09       Impact factor: 2.574

Review 10.  Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine.

Authors:  H G Bahnemann
Journal:  Vaccine       Date:  1990-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.